Okan GÜLBAHAR, Anastasios E. GERMENIS

Rediscovery of a forgotten disease: Hereditary Angioedema

PDF

___

1. Cicardi M, Aberer W, Banerji A, et. al. Classification, diagnosis, and approach to treatment for angioedema: consensus report from the Hereditary Angioedema International Working Group. Allergy. 2014;69(5):602-616. [Crossref]
2. Proper SP, Lavery WJ, Bernstein JA. Definition and classification of hereditary angioedema. Allergy Asthma Proc. 2020;41(Soppl 1):S03-S07. [Crossref]
3. Reshef A, Kidon M, Leibovich I. The story of angioedema: from Quincke to bradykinin. Clin Rev Allergy Immunol. 2016;51:121-139. [Crossref]
4. Maurer M. Urticaria and angioedema. Chem Immunol Allergy. 2014;100:101-104. [Crossref]
5. Barnett AF. Hereditary angioneurotic edema: a remarkable family history. Calif Med. 1948;69(5):376-380.
6. Donati M: De medica historia mirabile. Mantua, Osana, 1586, vol 7, chapt 3, p 304.
7. Mai FA. Stolpertus, ein junger Arzt am Krankenbette. Schwann & Götz, Mannheim, 1777, 1807.
8. Arnoldsson H, Belin L, Hallberg L, Helander E, Lindholm B, Westling H. Hereditary periodic oedema. Acta Med Scand. 1967;181(1):115-124. [Crossref]
9. Graves R. Clinical lectures on the practice of medicine. In: Major MH (ed) Classic descriptions of disease, 3rd edn. Charles C. Thomas, Springfield, 1843, pp 623-624.
10. Milton JL. On giant urticaria. Edinb Med J. 1876;22:513-526. [Crossref]
11. Quincke H. Uber akutes umschriebenes Hautoedem. Mschr Prakt Dermatol. 1882;1:160-169.
12. Strübing P. Uber acutes (angioneurotisches) Odem. Zeitschr F Klin Med. 1885;9:381.
13. Osler W. Hereditary angio-neurotic oedema. Am J Med Sci. 1888;95:362. [Crossref]
14. Crowder JR, Crowder TR. Five generations of angioneurotic edema. Arch Int Med. 1917;20:840. [Crossref]
15. Pensky J, Levy LR, Lepow ICH. Partial purification of a serum inhibitor of C’1-esterase. J Biol Chem. 1961;236:1674-1679. [Crossref]
16. Landerman N. Hereditary angioeneurotic edema: I. Case reports and review of the literature. J Allergy. 1962;33:316-329. [Crossref]
17. Donaldson VH, Evans RR. A biochemical abnormality in hereditary angioneurotic edema: absence of serum inhibitor of C’1-esterase. Am J Med. 1963;35:37-44. [Crossref]
18. Donaldson VH, Rosen FS. Action of complement in hereditary angioneurotic edema: the role of C’1-esterase. J Clin Invest. 1964;43(11):2204-2213. [Crossref]
19. Rosen FS, Pensky J, Donaldson V, Charache P. Hereditary angioneurotic edema: two genetic variants. Science. 1965;148(3672):957-958. [Crossref]
20. Schapira M, Silver LD, Scott CF, et al. Prekallikrein activation and high-molecular-weight kininogen consumption in hereditary angioedema. N Engl J Med. 1983;308(18):1050-1053. [Crossref]
21. Dunn JT, Silverberg M, Kaplan AP. The cleavage and formation of activated human Hageman factor by autodigestion and by kallikrein. J Biol Chem. 1982;257:1779-84. [Crossref]
22. Bock SC, Skriver K, Nielsen E, et al. Human C1 inhibitor: primary structure, cDNA cloning, and chromosomal localization. Biochemistry. 1986;25(15):4292-4301. [Crossref]
23. Theriault A, Whaley K, McPhaden AR, Boyd E, Connor JM. Regional assignment of the human C1-inhibitor gene to 11q11-q13.1. Hum Genet. 1990;84(5):477-479. [Crossref]
24. Nussberger J, Cugno M, Amstutz C, Cicardi M, Pellacani A, Agostoni A. Plasma bradykinin in angio-oedema. Lancet. 1998; 351:1693-7. [Crossref]
25. Caldwell JR, Ruddy S, Schur PH, Austen KF. Acquired C1 inhibitor deficiency in lymphosarcoma. Clin Immunol Immunopathol. 1972;1:39-52. [Crossref]
26. Gülbahar O. Angioedema without wheals: A clinical update. Balkan Med J. 2021;38(2): 73-81.
27. López Lera A. Pathophysiology and underlying mechanisms in hereditary angioedema. Balkan Med J. 2021;38(2): 82-88.
28. Valerieva A, Nedeva D, Yordanova V, Elena Petkova E, Staevska M. Therapeutic management of hereditary angioedema: past, present, and future. Balkan Med J. 2021;38(2): 89-103.
29. Bork K, Barnstedt SE, Koch P, Traupe H. Hereditary angioedema with normal C1-inhibitor activity in women. Lancet 2000;356(9225):213-217. [Crossref]
30. Binkley KE, Davis 3rd A. Clinical, biochemical, and genetic characterization of a novel estrogen-dependent inherited form of angioedema. J Allergy Clin Immunol. 2000;106(3):546-550. [Crossref]
31. Dewald G, Bork K. Missense mutations in the coagulation factor XII (Hageman factor) gene in hereditary angioedema with normal C1 inhibitor. Biochem Biophys Res Commun. 2006;343(4):1286-1289. [Crossref]
32. Magerl M, Germenis AE, Maas C, Maurer M. Hereditary angioedema with normal C1 Inhibitor: Update on evaluation and treatment. Immunol Allergy Clin North Am. 2017;37(3):571-584. [Crossref]
33. Germenis AE, Rijavec M, Veronez CL. Leveraging genetics for hereditary angioedema: A road map to precision medicine. Clin Rev Allergy Immunol. 2021 Jan 28. doi: 10.1007/s12016-021-08836-7. [Crossref]
34. Loules G, Parsopoulou F, Zamanakou M, et al. Deciphering the genetics of primary angioedema with normal levels of C1 inhibitor. J Clin Med. 2020;9(11):3402 [Crossref]
35. Germenis AE, Cicardi M. Driving towards Precision Medicine for angioedema without wheals. J Autoimmun. 2019;104:102312. [Crossref]
36. Wu MA, Bova M, Berra S, et al. The central role of endothelium in hereditary angioedema due to C1 inhibitor deficiency. Int Immunopharmacol. 2020;82:106304. [Crossref]
37. Ponard D, Gaboriaud C, Charignon D, et al. SERPING1 mutation update: Mutation spectrum and C1 Inhibitor phenotypes. Hum Mutat. 2020;41(1):38-57. [Crossref]
38. Vatsiou S, Zamanakou M, Loules G, et al. A novel deep intronic SERPING1 variant as a cause of hereditary angioedema due to C1-inhibitor deficiency. Allergol Int. 2020; 69(3):443-449. [Crossref]
39. Hujová P, Souček P, Grodecká L, et al. Deep intronic mutation in SERPING1 caused hereditary angioedema through pseudoexon activation. J Clin Immunol. 2020; 40(3):435-446. [Crossref]
40. Cicardi M, Igarashi T, Rosen FS, Davis AE 3rd. Molecular basis for the deficiency of complement 1 inhibitor in type I hereditary angioneurotic edema. J Clin Invest. 1987;79(3):698-702. [Crossref]
41. Haslund D, Ryø LB, Majidi SS, et al. Dominant-negative SERPING1 variants cause intracellular retention of C1 inhibitor in hereditary angioedema. J Clin Invest. 2019;129(1):388-405. [Crossref]
42. Suffritti C, Zanichelli A, Maggioni L, Bonanni E, Cugno M, Cicardi M. High-molecular-weight kininogen cleavage correlates with disease states in the bradykinin-mediated angioedema due to hereditary C1-inhibitor deficiency. Clin Exp Allergy. 2014;44(12):1503-1514. [Crossref]
43. Charignon D, Ghannam A, Ponard D, Drouet C. Hereditary C1 inhibitor deficiency is associated with high spontaneous amidase activity. Mol Immunol. 2017;85:120-122. [Crossref]
44. Lara-Marquez ML, Christiansen SC, Riedl MA, Herschbach J, Zuraw BL. Threshold-stimulated kallikrein activity distinguishes bradykinin- from histamine-mediated angioedema. Clin Exp Allergy. 2018;48(11):1429-1438. [Crossref]
45. Larrauri B, Hester CG, Jiang H, et al. sgp120 and the contact system in hereditary angioedema: A diagnostic tool in HAE with normal C1 inhibitor. Mol Immunol. 2020;119:27-34 [Crossref]
46. Kaplan AP, Maas C. The search for biomarkers in hereditary angioedema. Front Med. 2017;4:206. [Crossref]
47. Nicola S, Rolla G, Brussino L. Breakthroughs in hereditary angioedema management: a systematic review of approved drugs and those under research. Drugs Context. 2019;8:212605.[Crossref]
48. Bygum A, Aygören-Pürsün E, Beusterien K, et al. Burden of illness in hereditary angioedema: A conceptual model. Acta Derm Venereol. 2015;95(6):706-710. [Crossref]
49. Bork K, Davis-Lorton M. Overview of hereditary angioedema caused by C1-inhibitor deficiency: assessment and clinical management. Eur Ann Allergy Clin Immunol. 2013;45:7-16.
50. Busse PJ, Christiansen SC. Hereditary angioedema. N Engl J Med. 2020;382(12):1136- 1148. [Crossref]
51. Speletas M, Szilagyi A, Psarros F, et al. Hereditary angioedema: molecular and clinical differences among European populations. J Allergy Clin Immunol. 2015;135(2):570- 573. [Crossref]
52. Caccia S, Suffritti C, Carzaniga T, et al. Intermittent C1-inhibitor deficiency associated with recessive inheritance: Functional and structural insight. Sci Rep. 2018;8(1):977. [Crossref]
53. Margaglione M, D’Apolito M, Santocroce R, Maffione AB. Hereditary angioedema: Looking for bradykinin production and triggers of vascular permeability. Clin Exp Allergy. 2019;49(11):1395-1402. [Crossref]
54. Speletas M, Szilágyi A, Csuka D, et al. F12-46C/T polymorphism as modifier of the clinical phenotype of hereditary angioedema, Allergy. 2015;70(12):1661-1664. [Crossref]
55. Gianni P, Loules G, Zamanakou M, et al. Genetic determinants of the C1-INH deficiency angioedema (C1-INH-HAE) age of onset. Int J Allergy Immunol 2017;174(3- 4):200-204. [Crossref]
56. Rijavec M, Košnik M, Andrejević S, Karadža-Lapić L, Grivčeva-Panovska V, Korošec P. The functional promoter F12-46C/T variant predicts the asymptomatic phenotype of C1-INH-HAE. Clin Exp Allergy. 2019;49(11):1520-1522. [Crossref]
57. Iwaki T, Castellino F. Plasma levels of bradykinin are suppressed in factor XII-deficient mice. Thromb Haemost 2006;95(6):1003-1010. [Crossref]
58. Shariat-Madar Z, Mahdi F, Schmaier AH. Identification and characterization of prolylcarboxypeptidase as an endothelial cell prekallikrein activator. J Biol Chem. 2002;277(20):17962-17969. [Crossref]
59. Joseph K, Tholanikunnel BG, Kaplan AP. Heat shock protein 90 catalyzes activation of the prekallikrein-kininogen complex in the absence of factor XII. Proc Natl Acad Sci U S A. 2002;99(2):896-900. [Crossref]
60. Drouet C, Désormeaux A, Robillard J, et al. Metallopeptidase activities in hereditary angioedema: effect of androgen prophylaxis on plasma aminopeptidase P. J Allergy Clin Immunol. 2008;121(2):429-433. [Crossref]
61. De Maat S, Hofman ZLM, Maas C. Hereditary angioedema: the plasma contact system out of control. J Thromb Haemost. 2018;16(9):1674-1685. [Crossref]
62. Han ED, MacFarlane RC, Mulligan AN, Scafidi J, Davis AE 3rd. Increased vascular permeability in C1 inhibitor-deficient mice mediated by the bradykinin type 2 receptor. J Clin Invest. 2002;109:1057-63. [Crossref]
63. Kishimoto TK, Viswanathan K, Ganguly T, et al. Contaminated heparin associated with adverse clinical events and activation of the contact system. N Engl J Med. 2008;358:2457-2467.
64. Adam A, Montpas N, Keire D, et al. Bradykinin forming capacity of oversulfated chondroitin sulfate contaminated heparin in vitro. Biomaterials. 2010;31(22):5741- 5748. [Crossref]
65. Zhou ZH, Chen T, Arora K, Hyams K, Kozlowski S. Complement C1 esterase inhibitor levels linked to infections and contaminated heparin-associated adverse events. PLoS One. 2012;7(4):e34978. [Crossref]
66. Hofman ZLM, Relan A, Zeerleder S, Drouet C, Zuraw B, Hack CE. Angioedema attacks in patients with hereditary angioedema: Local manifestations of a systemic activation process. J Allergy Clin Immunol. 2016;138(2):359-366. [Crossref]
67. Hofman ZLM, Relan A, Hack CE. Hereditary Angioedema attacks: local swelling at multiple sites. Clin Rev Allergy Immunol. 2016;50(1):34-40. [Crossref]
68. Prematta MJ, Kemp JG, Gibbs JG, Mende C, Rhoads C, Craig TJ. Frequency, timing, and type of prodromal symptoms associated with hereditary angioedema attacks. Allergy Asthma Proc. 2009;30(5):506-511. [Crossref]
69. Magerl M, Doumoulakis G, Kalkounou I, et al. Characterization of prodromal symptoms in a large population of patients with hereditary angio-oedema. Clin Exp Dermatol. 2014;39(3):298-303. [Crossref]
70. Ghebrehiwet B, Geisbrecht BV, Xu X, Savitt AG, Peerschke EIB. The C1q Receptors: Focus on gC1qR/p33 (C1qBP, p32, HABP-1). Semin Immunol. 2019;45:101338. [Crossref]
71. Taylor SL, Wahl-Jensen V, Copeland AM, Jahrling PB, Schmaljohn CS. Endothelial cell permeability during hantavirus infection involves factor XII-dependent increased activation of the kallikrein kinin system. PLoS Pathog. 2013; 9(7):e1003470. [Crossref]
72. Gershom ES, Sutherland MR, Lollar P, Pryzdial EL. Involvement of the contact phase and intrinsic pathway in herpes simplex virus-initiated plasma coagulation. J Thromb Haemost. 2010;8(5):1037-1043. [Crossref]
73. Loffredo S, Bova M, Suffritti C, et al. Elevated plasma levels of vascular permeability factors in C1 inhibitor-deficient hereditary angioedema. Allergy. 2016;71(7):989-996. [Crossref]
74. Bova M, Suffritti C, Bafunno V, et al. Impaired control of the contact system in hereditary angioedema with normal C1-inhibitor. Allergy. 2020;75(6):1394-1403. [Crossref]